MyFinsight
Home
Blog
About
Selling, general and
administrative
-$213K
(-110.51%↓ Y/Y)
Net revenue
$12,824K
(25.06%↑ Y/Y)
Total costs and
expenses
-$203K
(-102.25%↓ Y/Y)
Research and development
$10K
(-97.73%↓ Y/Y)
Income from operations
$13,027K
(-7.47%↓ Y/Y)
Net income from
discontinued operations...
$12,716K
(-96.29%↓ Y/Y)
Loss (gain) on sale
transactions, net
-$311K
(-100.09%↓ Y/Y)
Net income (gain)
-$20,631K
(-106.93%↓ Y/Y)
Net income from
discontinued operations, net...
$12,716K
(-96.29%↓ Y/Y)
Net loss from
continuing operations
-$33,347K
(25.67%↑ Y/Y)
Loss from continuing
operations before income...
-$33,347K
(25.67%↑ Y/Y)
Other income
(expense), net
$1,307K
(-54.95%↓ Y/Y)
Toripalimab
$13,613K
(36.69%↑ Y/Y)
Product And Service
Other
$694K
(135.25%↑ Y/Y)
Loss from operations
-$32,331K
(28.92%↑ Y/Y)
Interest expense
$2,323K
(2.02%↑ Y/Y)
Net revenue
$14,307K
(39.53%↑ Y/Y)
Total costs and
expenses
$46,638K
(-16.33%↓ Y/Y)
Research and development
$21,442K
(-18.49%↓ Y/Y)
Selling, general and
administrative
$20,954K
(-19.53%↓ Y/Y)
Cost of goods sold
$4,242K
(24.95%↑ Y/Y)
Back
Back
Income Statement
Coherus Oncology, Inc. (CHRS)
Coherus Oncology, Inc. (CHRS)
source: myfinsight.com